$HRTX
Heron Therapeutics Inc

2017 Q1 Form 10-Q Financial Statement

#000119312517165100 Filed on May 10, 2017

View on sec.gov

Income Statement

Concept 2017 Q1 2016 Q1
Revenue $3.632M
YoY Change
Cost Of Revenue $1.186M
YoY Change
Gross Profit $2.446M
YoY Change
Gross Profit Margin 67.35%
Selling, General & Admin $18.36M $17.22M
YoY Change 6.63% 194.06%
% of Gross Profit 750.65%
Research & Development $33.38M $16.09M
YoY Change 107.46% 10.95%
% of Gross Profit 1364.84%
Depreciation & Amortization $329.0K $240.0K
YoY Change 37.08% 60.0%
% of Gross Profit 13.45%
Operating Expenses $52.93M $33.31M
YoY Change 58.89% 63.61%
Operating Profit -$49.30M -$33.31M
YoY Change 47.99% 63.61%
Interest Expense $1.030M $133.0K
YoY Change 674.44% -42.67%
% of Operating Profit
Other Income/Expense, Net -$1.030M -$133.0K
YoY Change 674.44% -36.67%
Pretax Income -$50.33M -$33.45M
YoY Change 50.46% 62.62%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$50.33M -$33.45M
YoY Change 50.48% 62.59%
Net Earnings / Revenue -1385.71%
Basic Earnings Per Share
Diluted Earnings Per Share -$996.0K -$923.3K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q1 2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $165.2M $100.4M
YoY Change 64.54% 80.58%
Cash & Equivalents $83.51M $68.02M
Short-Term Investments $81.70M $32.40M
Other Short-Term Assets $3.400M $5.100M
YoY Change -33.33% 466.67%
Inventory $4.641M $2.744M
Prepaid Expenses
Receivables $10.33M
Other Receivables $0.00
Total Short-Term Assets $183.6M $108.2M
YoY Change 69.7% 91.5%
LONG-TERM ASSETS
Property, Plant & Equipment $5.680M $3.645M
YoY Change 55.83% 21.66%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $263.0K
YoY Change
Total Long-Term Assets $5.943M $3.645M
YoY Change 63.05% 16.6%
TOTAL ASSETS
Total Short-Term Assets $183.6M $108.2M
Total Long-Term Assets $5.943M $3.645M
Total Assets $189.6M $111.8M
YoY Change 69.48% 87.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.477M $6.861M
YoY Change -34.75% 187.91%
Accrued Expenses $24.60M $9.900M
YoY Change 148.48% 32.0%
Deferred Revenue
YoY Change
Short-Term Debt $3.100M $0.00
YoY Change
Long-Term Debt Due $2.400M
YoY Change 41.18%
Total Short-Term Liabilities $37.40M $19.17M
YoY Change 95.09% 64.89%
LONG-TERM LIABILITIES
Long-Term Debt $50.00M $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $50.00M $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $37.40M $19.17M
Total Long-Term Liabilities $50.00M $0.00
Total Liabilities $87.40M $19.20M
YoY Change 355.2% 65.52%
SHAREHOLDERS EQUITY
Retained Earnings -$636.3M -$446.3M
YoY Change 42.58% 32.9%
Common Stock $537.0K $363.0K
YoY Change 47.93% 22.64%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $102.2M $92.68M
YoY Change
Total Liabilities & Shareholders Equity $189.6M $111.8M
YoY Change 69.48% 87.58%

Cashflow Statement

Concept 2017 Q1 2016 Q1
OPERATING ACTIVITIES
Net Income -$50.33M -$33.45M
YoY Change 50.48% 62.59%
Depreciation, Depletion And Amortization $329.0K $240.0K
YoY Change 37.08% 60.0%
Cash From Operating Activities -$50.58M -$32.35M
YoY Change 56.35% 64.48%
INVESTING ACTIVITIES
Capital Expenditures $938.0K $834.0K
YoY Change 12.47% 154.27%
Acquisitions
YoY Change
Other Investing Activities -$43.98M $23.49M
YoY Change -287.23%
Cash From Investing Activities -$44.92M $22.66M
YoY Change -298.25% -7007.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $163.7M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 165.6M 2.530M
YoY Change 6445.34% -12.09%
NET CHANGE
Cash From Operating Activities -50.58M -32.35M
Cash From Investing Activities -44.92M 22.66M
Cash From Financing Activities 165.6M 2.530M
Net Change In Cash 70.10M -7.164M
YoY Change -1078.49% -58.15%
FREE CASH FLOW
Cash From Operating Activities -$50.58M -$32.35M
Capital Expenditures $938.0K $834.0K
Free Cash Flow -$51.52M -$33.19M
YoY Change 55.25% 65.95%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q1 hrtx Valuation Allowances And Reserves Provisions
ValuationAllowancesAndReservesProvisions
1482000
CY2017Q1 hrtx Accrued Clinical Liabilities
AccruedClinicalLiabilities
11224000
CY2016Q4 hrtx Accrued Clinical Liabilities
AccruedClinicalLiabilities
13207000
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1960000
CY2017Q1 hrtx Amortization Of Shortterm Investment Premium
AmortizationOfShorttermInvestmentPremium
-13000
CY2016Q1 hrtx Amortization Of Shortterm Investment Premium
AmortizationOfShorttermInvestmentPremium
145000
CY2011Q3 hrtx Common Shares Registered For Resale In Connection With Convertible Notes
CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes
3500000
CY2011Q2 hrtx Convertible Debt Issuable In Connection With Private Placement1
ConvertibleDebtIssuableInConnectionWithPrivatePlacement1
4500000
CY2017Q1 hrtx Convertible Notes Payable Related Parties Current
ConvertibleNotesPayableRelatedPartiesCurrent
3096000
CY2016Q4 hrtx Convertible Notes Payable Related Parties Current
ConvertibleNotesPayableRelatedPartiesCurrent
2911000
CY2017Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-30000
CY2017Q1 hrtx Impact On Basic And Diluted Net Loss Per Common Share In Dollars Per Share
ImpactOnBasicAndDilutedNetLossPerCommonShareInDollarsPerShare
0.16
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-17000
CY2016Q1 hrtx Impact On Basic And Diluted Net Loss Per Common Share In Dollars Per Share
ImpactOnBasicAndDilutedNetLossPerCommonShareInDollarsPerShare
0.15
CY2017Q1 hrtx Increase Decrease In Clinical Liabilities
IncreaseDecreaseInClinicalLiabilities
-1983000
CY2017Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
737953000
CY2016Q1 hrtx Increase Decrease In Clinical Liabilities
IncreaseDecreaseInClinicalLiabilities
-1496000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6814000
CY2017Q1 hrtx Stock Issued During Period Shares Stock Options Exercised Net
StockIssuedDuringPeriodSharesStockOptionsExercisedNet
197000
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
564343000
CY2017Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
4477000
CY2017Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
10327000
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8021000
CY2016Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5355000
CY2017Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
185000
CY2016Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
166000
CY2017Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2016Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2017Q1 us-gaap Assets
Assets
189558000
CY2016Q4 us-gaap Assets
Assets
67482000
CY2017Q1 us-gaap Assets Current
AssetsCurrent
183615000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
62143000
CY2017Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
122124000
CY2016Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
37724000
CY2017Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
CY2017Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
30000
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
17000
CY2017Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
122154000
CY2016Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
37741000
CY2017Q1 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
81703000
CY2016Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
37724000
CY2017Q1 us-gaap Available For Sale Securities Gross Realized Gains
AvailableForSaleSecuritiesGrossRealizedGains
0
CY2016Q1 us-gaap Available For Sale Securities Gross Realized Gains
AvailableForSaleSecuritiesGrossRealizedGains
0
CY2017Q1 us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
0
CY2016Q1 us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
0
CY2017Q1 us-gaap Basis Of Accounting
BasisOfAccounting
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div></div><div style="display: inline; font-weight: bold;">.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B</div><div style="display: inline; font-weight: bold;">asis of Presentation</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;) for interim financial information and with the instructions to Form <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>-Q and Article <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div> of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> are not necessarily indicative of the results that <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> be expected for other quarters or the year ending <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div> The condensed consolidated balance sheet as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> has been derived from the audited financial statements as of that date, but does not include all of the information and disclosures required by GAAP. For more complete financial information, these unaudited condensed consolidated financial statements and the notes thereto should be read in conjunction with the audited financial statements included in our Annual Report on Form</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>-K for the fiscal year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> which was filed with the SEC on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">23,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div></div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">.</div></div></div>
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13414000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75180000
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
83513000
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68016000
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
70099000
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-7164000
CY2017Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
165200000
CY2017Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
40400000
CY2017Q1 us-gaap Common Stock Value
CommonStockValue
537000
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
394000
CY2017Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-50342000
CY2016Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33404000
CY2017Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Concentration of Risk</div></div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Cash, cash equivalents and short-term investments are financial instruments that potentially subject us to concentrations of credit risk. We deposit our cash in financial institutions. At times, such deposits <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> be in excess of insured limits. We <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> also invest our excess cash in money market funds, U.S. government and agencies, corporate debt securities and commercial paper. We have established guidelines relative to our diversification of our cash investments and their maturities in an effort to maintain safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Sales of SUSTOL to ASD Specialty Healthcare, Inc. and Cardinal Health, Inc. each accounted for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10%</div> or more of our net revenues for the quarter ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div> The loss of either of these customers could materially and adversely affect our business, results of operations, financial condition and cash flows. </div></div></div></div></div>
CY2017Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
1186000
CY2016Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
CY2017Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
5235000
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1099000
CY2017Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
329000
CY2016Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
238000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.92
CY2017Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6122000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8414000
CY2017Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
79400000
CY2017Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y328D
CY2017Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-5000
CY2016Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6742000
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5367000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-50329000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-33445000
CY2017Q1 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
50000000
CY2016Q4 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
50000000
CY2017Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2337000
CY2016Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3561000
CY2017Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
8367000
CY2016Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
CY2017Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
4136000
CY2016Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
CY2017Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-2292000
CY2016Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1859000
CY2017Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-699000
CY2016Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2744000
CY2017Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
1091000
CY2016Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-852000
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-274000
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1420000
CY2017Q1 us-gaap Interest Expense
InterestExpense
1030000
CY2016Q1 us-gaap Interest Expense
InterestExpense
133000
CY2017Q1 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
100000
CY2016Q1 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
100000
CY2017Q1 us-gaap Interest Paid
InterestPaid
1000000
CY2016Q1 us-gaap Interest Paid
InterestPaid
CY2017Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
3000000
CY2017Q1 us-gaap Inventory Net
InventoryNet
4641000
CY2016Q4 us-gaap Inventory Net
InventoryNet
5340000
CY2017Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1600000
CY2017Q1 us-gaap Liabilities
Liabilities
87398000
CY2016Q4 us-gaap Liabilities
Liabilities
88733000
CY2017Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
189558000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
67482000
CY2017Q1 us-gaap Liabilities Current
LiabilitiesCurrent
37398000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
38733000
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
165597000
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2530000
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-44917000
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
22657000
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-50581000
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-32351000
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33384000
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16092000
CY2017Q1 us-gaap Restructuring And Related Cost Expected Cost1
RestructuringAndRelatedCostExpectedCost1
10300000
CY2017Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-636300000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-585971000
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
52931000
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
33312000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-49299000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-33312000
CY2017Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
7244000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
6288000
CY2017Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
263000
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
263000
CY2017Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-13000
CY2016Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
41000
CY2017Q1 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
-25395000
CY2016Q1 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
-23491000
CY2017Q1 us-gaap Payments For Restructuring
PaymentsForRestructuring
3000000
CY2017Q1 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
69374000
CY2016Q1 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
938000
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
834000
CY2017Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3431000
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3705000
CY2011Q2 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
4300000
CY2017Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
163700000
CY2017Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
163747000
CY2016Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
CY2017Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1850000
CY2016Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2530000
CY2017Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5680000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5076000
CY2017Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
3632000
CY2016Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
CY2017Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
197000
CY2017Q1 us-gaap Stockholders Equity
StockholdersEquity
102160000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-21251000
CY2017Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
11619000
CY2016Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
11853000
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
8021000
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
5355000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
215000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
19.73
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
416000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11845000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11849000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.44
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.40
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
9.38
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
13.65
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y219D
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y171D
CY2017Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Use of Estimates</div></div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. Our critical accounting policies that involve significant judgment and estimates include revenue recognition, inventory, accrued clinical liabilities, income taxes and stock-based compensation. Actual results could differ materially from those estimates.</div></div></div></div></div>
CY2016Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
342000
CY2017Q1 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
1462000
CY2017Q1 us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
362000
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
50530000
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36229000

Files In Submission

Name View Source Status
0001193125-17-165100-index-headers.html Edgar Link pending
0001193125-17-165100-index.html Edgar Link pending
0001193125-17-165100.txt Edgar Link pending
0001193125-17-165100-xbrl.zip Edgar Link pending
d368962d10q.htm Edgar Link pending
d368962dex311.htm Edgar Link pending
d368962dex312.htm Edgar Link pending
d368962dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
hrtx-20170331.xml Edgar Link completed
hrtx-20170331.xsd Edgar Link pending
hrtx-20170331_cal.xml Edgar Link unprocessable
hrtx-20170331_def.xml Edgar Link unprocessable
hrtx-20170331_lab.xml Edgar Link unprocessable
hrtx-20170331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending